PeptideDB

Pozelimab

CAS: 2096328-94-6 F: W:

Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases[1].
Invitro Pozelimab 与人 C5 和食蟹猴 C5 结合的 Kd 值分别为 262 pM 和 8.55 nM 在 37˚C,pH7.4 的条件下[1]。Pozelimab 阻断代表性通路 (CP) 介导的人和食蟹猴血清溶血,IC50 值分别为 2.8 和 20 nM 在 37˚C,pH7.4 的条件下[1]。Pozelimab 阻断替代途径 (AP) 介导的正常人和食蟹猴血清溶血,IC50 值分别为 26 和 8.9 nM 在 37˚C,pH7.4 的条件下[1]。Pozelimab 与人 C5,食蟹猴 C5,人 R885C C5 和人 C5b,6 结合的 Kd 值分别为 0.189,2.73,0.422,0.465 和 0.137 nM 在 25˚C,pH7.4 时[1]。
In Vivo Pozelimab (15 mg/kg;皮下注射,1 次) 在雄性和雌性 C5hu/hu 小鼠中,具有较长的药代动力学参数,半衰期约为 13 天[1]。 Animal Model:
Name Pozelimab
CAS 2096328-94-6
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Reference [1]. Latuszek A, et al. Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS One. 2020 May 8;15(5):e0231892.